These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1364 related items for PubMed ID: 16314620

  • 1. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 2. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A.
    Haematologica; 2006 Jul 01; 91(7):968-71. PubMed ID: 16757414
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov 01; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 4. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 01; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 5. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ.
    J Oral Maxillofac Surg; 2007 Jul 01; 65(7):1328-31. PubMed ID: 17577497
    [Abstract] [Full Text] [Related]

  • 6. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, Gilardino MO, Aglietta M.
    Acta Oncol; 2007 Jul 01; 46(5):664-8. PubMed ID: 17562443
    [Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA, López Tarruella S, García Paredes B, Rodríguez Lajusticia L, Villalobos L, Díaz Rubio E.
    Med Oral Patol Oral Cir Bucal; 2007 Sep 01; 12(5):E351-6. PubMed ID: 17767097
    [Abstract] [Full Text] [Related]

  • 8. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE, Sawatari Y, Fortin M, Broumand V.
    J Oral Maxillofac Surg; 2005 Nov 01; 63(11):1567-75. PubMed ID: 16243172
    [Abstract] [Full Text] [Related]

  • 9. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA.
    Cancer; 2009 Apr 15; 115(8):1631-7. PubMed ID: 19156913
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
    Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M.
    Gynecol Oncol; 2009 Mar 15; 112(3):605-9. PubMed ID: 19136147
    [Abstract] [Full Text] [Related]

  • 11. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF.
    Ann N Y Acad Sci; 2011 Feb 15; 1218():47-54. PubMed ID: 20946574
    [Abstract] [Full Text] [Related]

  • 12. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T, Cheng A, Stein B, Goss A.
    J Oral Maxillofac Surg; 2007 Mar 15; 65(3):415-23. PubMed ID: 17307586
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K.
    J Clin Oncol; 2009 Nov 10; 27(32):5356-62. PubMed ID: 19805682
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ, Ramalingam L, Zacharin MR.
    Clin Endocrinol (Oxf); 2008 Jun 10; 68(6):863-7. PubMed ID: 18221397
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
    Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S.
    J Clin Oncol; 2008 Oct 01; 26(28):4634-8. PubMed ID: 18574158
    [Abstract] [Full Text] [Related]

  • 16. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Crawford BS, McNulty RM, Kraut EH, Turowski RC.
    Cancer Invest; 2009 Dec 01; 27(10):984-8. PubMed ID: 19909013
    [Abstract] [Full Text] [Related]

  • 17. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
    Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N.
    J Oral Maxillofac Surg; 2009 Apr 01; 67(4):850-5. PubMed ID: 19304045
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G.
    Oral Oncol; 2008 Sep 01; 44(9):857-69. PubMed ID: 18282788
    [Abstract] [Full Text] [Related]

  • 19. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE, Umland EM.
    Pharmacotherapy; 2008 May 01; 28(5):667-77. PubMed ID: 18447663
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates and jaw osteonecrosis: the UAMS experience.
    Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC.
    Otolaryngol Head Neck Surg; 2007 Mar 01; 136(3):396-400. PubMed ID: 17321866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.